JP6726182B2 - 真皮結合組織中のフィブロエラスチンの回復用途のアミノ酸系組成物 - Google Patents
真皮結合組織中のフィブロエラスチンの回復用途のアミノ酸系組成物 Download PDFInfo
- Publication number
- JP6726182B2 JP6726182B2 JP2017529035A JP2017529035A JP6726182B2 JP 6726182 B2 JP6726182 B2 JP 6726182B2 JP 2017529035 A JP2017529035 A JP 2017529035A JP 2017529035 A JP2017529035 A JP 2017529035A JP 6726182 B2 JP6726182 B2 JP 6726182B2
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- amino acid
- amino acids
- sterile
- collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 47
- 150000001413 amino acids Chemical class 0.000 title claims description 36
- 210000002808 connective tissue Anatomy 0.000 title description 11
- 230000002500 effect on skin Effects 0.000 title description 7
- 238000011084 recovery Methods 0.000 title description 2
- 108010014258 Elastin Proteins 0.000 claims description 38
- 229940024606 amino acid Drugs 0.000 claims description 36
- 235000001014 amino acid Nutrition 0.000 claims description 35
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 15
- 230000014509 gene expression Effects 0.000 claims description 15
- 229920002674 hyaluronan Polymers 0.000 claims description 15
- 229960003160 hyaluronic acid Drugs 0.000 claims description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 11
- 102000004266 Collagen Type IV Human genes 0.000 claims description 10
- 108010042086 Collagen Type IV Proteins 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 102100033167 Elastin Human genes 0.000 claims description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 7
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 7
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- 239000004395 L-leucine Substances 0.000 claims description 3
- 235000019454 L-leucine Nutrition 0.000 claims description 3
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims description 3
- 229930182821 L-proline Natural products 0.000 claims description 3
- 229960004308 acetylcysteine Drugs 0.000 claims description 3
- 229960003767 alanine Drugs 0.000 claims description 3
- 229960002449 glycine Drugs 0.000 claims description 3
- 229960003136 leucine Drugs 0.000 claims description 3
- 229960002429 proline Drugs 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- -1 transdermal patch Substances 0.000 claims description 3
- 229960004295 valine Drugs 0.000 claims description 3
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims description 2
- 235000013878 L-cysteine Nutrition 0.000 claims description 2
- 239000004201 L-cysteine Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 229940014041 hyaluronate Drugs 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000008174 sterile solution Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 102000016942 Elastin Human genes 0.000 description 29
- 229920002549 elastin Polymers 0.000 description 28
- 102000008186 Collagen Human genes 0.000 description 15
- 108010035532 Collagen Proteins 0.000 description 15
- 229920001436 collagen Polymers 0.000 description 15
- 210000002950 fibroblast Anatomy 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 8
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 8
- 206010051246 Photodermatosis Diseases 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 230000008845 photoaging Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 210000002744 extracellular matrix Anatomy 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 229920002683 Glycosaminoglycan Polymers 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 102000016387 Pancreatic elastase Human genes 0.000 description 3
- 108010067372 Pancreatic elastase Proteins 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 210000004177 elastic tissue Anatomy 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 229960003646 lysine Drugs 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 238000011222 transcriptome analysis Methods 0.000 description 3
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 101150101095 Mmp12 gene Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- KIUKXJAPPMFGSW-YXBJCWEESA-N (2s,4s,5r,6s)-6-[(2s,3r,5s,6r)-3-acetamido-2-[(3s,4r,5r,6r)-6-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@@H]3[C@@H]([C@@H](O)C(O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)C(C(O)=O)O1 KIUKXJAPPMFGSW-YXBJCWEESA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 101150108568 ELN gene Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 208000019028 Epidermal thickening Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 1
- 101001010513 Homo sapiens Leukocyte elastase inhibitor Proteins 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010063562 Radiation skin injury Diseases 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 206010040869 Skin hypoplasia Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000036570 collagen biosynthesis Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 108091007167 extracellular matrix enzymes Proteins 0.000 description 1
- 102000036444 extracellular matrix enzymes Human genes 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000003208 gene overexpression Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000001724 microfibril Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000025600 response to UV Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
- A61K8/022—Powders; Compacted Powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
真皮は、支持ならびに栄養保持機能を発揮し、そして、全体として、強度、柔軟性、張りおよび代謝生存性を皮膚に与えている、皮膚の中央領域である。主に、それぞれ、配糖体の性質、および、糖ペプチドの性質の親水性物質である、グリコサミノグリカン(GAGs)およびプロテオグリカン(PGs)により構成される、間質マトリックスを継続的に再生成している、間葉系の起源の特異化した細胞である、繊維芽細胞と称される細胞を含んでいる。皮膚に強度と健康な状態を与える、全ての繊維性タンパク質が、その中にはめ込まれている、ゲル形状の親水性の網目を構成している、多量の水を、前記高分子は、維持している。
皮膚の老化および光老化における、真皮表皮組織の弾性機能の進行性低下に関与する、主要な現象の一つは、皮膚の細胞外マトリックス(ECM)ならびに、コラーゲンとエラスチン タンパク質の再生を担当する細胞である、繊維芽細胞による生合成活性の進行性欠失により、代表される。この現象の結果、新たな構造性の皮膚タンパク質ならびに親水性の細胞外マトリックスの合成が不十分または低い場合には、エラスターゼ、メタロプロテアーゼ、コラゲナーゼおよびゲラチナーゼと称される、特異的な分解酵素による、それらの分解が増加する[13,14,15]。加齢繊維芽細胞のミトコンドリア、ならびに、マクロファージ内で、高発現され、そして、合成される、前記の酵素が、「合成−破砕」平衡を、破砕側にシフトさせると、緩やかであるが、しかし進行性である、組織の劣化に誘導され、そして、組織は、緻密さの低下、弾力性の低下、ならびに、含水性の低下(GAG,PG,ならびに、繊維状エラスチン成分の不足)となる。部分的には生理的であるが、種々の環境的ならびに遺伝子的要因により悪化されている、前記の現象を、阻害、少なくとも、限定するためには、後者が存在している、全ての領域においては、繊維芽細胞中の構造性タンパク質(トロポエラスチンおよびコラーゲン)の合成を誘導する、遺伝子の発現を促進する、そして、同時に、メタロプロテアーゼ、特には、コラーゲンとエラスチンの劣化に特異的なもの(コラゲナーゼとエラスターゼ)のコードに関与する、遺伝子の発現を低減させることが必要である。
本発明は、トロポエラスチン(ELN)、リシンオキシダーゼ(LOXL−1)ならびにIV型コラーゲン(COL4A1)をコードする遺伝子の発現を選択的に誘起し、また、メタロエラスターゼ類をコードする遺伝子の発現を阻害する、アミノ酸の混合物を含有する組成物に関する。
イン ビトロにおける、トランスクリプトーム解析ならびにプロテオーム解析を用いることで、ヒト線維芽細胞を120時間培養すると、トロポエラスチン(ELN)ならびにIV型コラーゲン(COLIV)をコードする遺伝子の発現の増加を、該アミノ酸の混合物が誘導することが見出された。驚くことに、該アミノ酸のうちの一つでも、除去されている、あるいは、重量比が、相違しているならば、前記の効果は、もはや、見出されない。
ヒアルロン酸ナトリウム塩の滅菌水性溶液
ヒアルロン酸ナトリウム塩の滅菌水性溶液
ヒアルロン酸ナトリウム塩の滅菌水性溶液
アミノ酸とヒアルロン酸ナトリウム塩に基づく、局所用ハイドロゲル
経口用溶液用の小袋(スティックパック)
保存剤:安息香酸ナトリウム、ソルビン酸カリウム;
pH調整剤:クエン酸、クエン酸ナトリウム。
細胞外マトリックスの構造性成分の産生、特には、エラスチンの新たな合成を活性化し、ならびに、弾性繊維のより効率的な沈積(弾性繊維形成)を容易にし、同時に、コラーゲンの活性化を持続させることにおける、本発明にかかるアミノ酸混合物の有効性を、対照混合物ならびにヒアルロン酸混合物との比較によって、評価した。
この試験には、処理を施していない繊維芽細胞(生理学的応答)に相当する、陰性対照が含まれている。コラーゲンを構成しているアミノ酸(Gly,L−Pro,L−Lys,L−leu)のみで構成されている、混合物Aは、有意な遺伝子発現を誘起しなかった。反対に、試験した6種のアミノ酸を含有する、コラーゲンとエラスチンの双方中で、最も発現されているアミノ酸からなる、二つの混合物CおよびDは、120時間後、ELN(エラスチン)遺伝子ならびにCOLIV(IV型コラーゲン)遺伝子の有意な変化を引き起こした。
図2中のグラフは、必要に応じて、ヒアルロン酸の組み合わせた、特定のアミノ酸混合物のみが、細胞外マトリックス タンパク質の生合成を調節することができ、特には、弾性繊維形成を促進できることを査証する、トランスクリプトーム解析法に基づいて実施された、単層ヒト繊維芽細胞試験の結果を示している。本出願中に開示される比率に従って組み合わされた、アミノ酸混合物のみが、コラーゲン(特には、IV型コラーゲン)の活性化をさらに高めるとともに、エラスチンの遺伝子ならびにタンパク質の発現を増加させている。
この試験の結果は、本発明にかかる混合物のみは、該二種のタンパク質の有意な産生を促進していることを査証している。従って、誘導する機構が存在することのみでなく、産生されるmRNAは、機能性のタンパク質をコードしていることも、査証している。
1. Bashir, MM et al. (1989), J Biol Chem 264, 8887-8891.
2. Chen, Z et al., (2009), Exp Dermatol 18, 378-386.
3. Indik Z et al., (1989), Am J Med Genet 34, 81-90.
4. Cenizo V et al., (2006), Exp Dermatol 15, 574-581.
5. Maki et al., (2005), Am J Pathol 167, 927-936.
6. Noblesse et al., (2004), J Invest Dermatol 122, 621-630.
7. Abreu-Velez AM et al., N Am J Med Sci. 2012 Jan;4(1):1-8.
8. Vazquez F et al., Maturitas. 1996 Nov;25(3):209-15.
9. Lupo MP et al., (2007). Cosmeceutical peptides. Dermatol Ther 20, 343-349.
10. Reddy B et al., Bioactive oligopeptides in dermatology: Part I. Exp Dermatol. 2012 Aug;21(8):563-8. doi: 10.1111/j.1600-0625.2012.01528.x. Epub 2012 Jun 4.
11. Proksch E et al., Skin Pharmacol Physiol. 2014;27(3):113-9.
12. Dioguardi FS, (2008) Nov-Cec;26(6):636-40.
13. Fisher GJ et al., J Invest Dermatol. 2001 Aug;117(2):219-26.
14. Rijken F et al., J Investig Dermatol Symp Proc. 2009 Aug;14(1):67-72. doi: 10.1038/jidsymp.2009.15.
15. Quan T et al., J Investig Dermatol Symp Proc. 2009 Aug;14(1):20-4. doi: 10.1038/jidsymp.2009.8.
16. Chung JH et al., J Invest Dermatol. 2002 Aug;119(2):507-12.
17. Schoepe S et al., Exp Dermatol. 2006 Jun;15(6):406-20.
Claims (11)
- L−システインないしはN−アセチル−システインを、全アミノ酸混合物の1〜20質量%の範囲の重量比率で、さらに含有していることを特徴とする、請求項1に記載の組成物。
- 経口用である、請求項1〜5のいずれか一項に記載の組成物。
- 液剤、顆粒剤、分散性粉末剤、錠剤、あるいは、カプセル剤の形状である、請求項6に記載の組成物。
- 500,000〜3.000,000 Daの範囲の平均分子量を具える、ヒアルロン酸ないしはその塩を、全アミノ酸混合物の0.01〜3質量%の範囲の重量比率で、さらに含有している
ことを特徴とする、請求項1〜5のいずれか一項に記載の組成物。 - 前記ヒアルロン酸ないしはその塩が、ヒアルロン酸ナトリウムである請求項8に記載の組成物。
- 外用または、注入用である、請求項8または9に記載の組成物。
- ゲル、軟膏、乳剤、経皮吸収パッチ、滅菌溶液、または、ヒアルロン酸塩の滅菌水性溶液を用いて再構成するように設計されている、滅菌アミノ酸粉末の形状である、請求項10に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2014A002084 | 2014-12-04 | ||
ITMI20142084 | 2014-12-04 | ||
PCT/IB2015/059330 WO2016088078A1 (en) | 2014-12-04 | 2015-12-03 | Aminoacid-based composition for fibroelastin recovery in dermal connective tissues |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017536388A JP2017536388A (ja) | 2017-12-07 |
JP6726182B2 true JP6726182B2 (ja) | 2020-07-22 |
Family
ID=52463041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017529035A Active JP6726182B2 (ja) | 2014-12-04 | 2015-12-03 | 真皮結合組織中のフィブロエラスチンの回復用途のアミノ酸系組成物 |
Country Status (22)
Country | Link |
---|---|
US (1) | US10272059B2 (ja) |
EP (1) | EP3226854B1 (ja) |
JP (1) | JP6726182B2 (ja) |
KR (1) | KR102429451B1 (ja) |
CN (1) | CN106999390A (ja) |
AU (1) | AU2015356587B2 (ja) |
BR (1) | BR112017011476B1 (ja) |
CA (1) | CA2969383C (ja) |
CY (1) | CY1123040T1 (ja) |
DK (1) | DK3226854T3 (ja) |
ES (1) | ES2777775T3 (ja) |
LT (1) | LT3226854T (ja) |
MX (1) | MX368900B (ja) |
MY (1) | MY185991A (ja) |
PH (1) | PH12017501003B1 (ja) |
PL (1) | PL3226854T3 (ja) |
RS (1) | RS60268B1 (ja) |
RU (1) | RU2704032C2 (ja) |
SA (1) | SA517381725B1 (ja) |
SG (1) | SG11201704423SA (ja) |
UA (1) | UA120627C2 (ja) |
WO (1) | WO2016088078A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
IT201700075026A1 (it) * | 2017-07-04 | 2019-01-04 | Professional Derma Sa | Composizioni iniettabili per filler dermico |
EP3668499A1 (en) | 2017-08-14 | 2020-06-24 | Axcella Health Inc. | Amino acid compositions for the treatment of liver disease |
EP3810123A1 (en) | 2018-06-20 | 2021-04-28 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
KR102226810B1 (ko) * | 2020-09-02 | 2021-03-15 | 주식회사 엘라스틱랩 | 연결 조직 중 엘라스틴 및 콜라겐 생합성 증진용 조성물 |
US20230148647A1 (en) * | 2020-09-02 | 2023-05-18 | Elastic Lab Inc. | Composition for promoting biosynthesis of elastin and collagen in connective tissue |
IT202100023903A1 (it) * | 2021-09-16 | 2023-03-16 | Professional Derma Sa | Composizione ad uso cosmetico |
CN115670969B (zh) * | 2022-11-08 | 2023-11-07 | 瑞玞生物医学(深圳)有限公司 | 一种刺激弹性蛋白形成的组合物 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2185646T3 (es) * | 1992-12-22 | 2003-05-01 | Baxter Int | Soluciones de aminoacido mejoradas para el tratamiento de pacientes de dialisis peritoneal. |
JP3553992B2 (ja) * | 1993-05-28 | 2004-08-11 | 独立行政法人理化学研究所 | 代謝調節剤 |
US6159485A (en) * | 1999-01-08 | 2000-12-12 | Yugenic Limited Partnership | N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use |
CN1126541C (zh) * | 1999-12-03 | 2003-11-05 | 中国人民解放军军事医学科学院放射医学研究所 | 新型复合氨基酸组合物 |
JP2004123564A (ja) * | 2002-09-30 | 2004-04-22 | Inst Of Physical & Chemical Res | 中枢機能改善用アミノ酸組成物 |
FR2849383B1 (fr) | 2002-12-26 | 2005-09-30 | Jean Noel Thorel | Composition trophique en milieu aqueux, et ses applications, notamment en ophtalmologie |
DE10313200A1 (de) | 2003-03-19 | 2004-10-07 | Ami-Agrolinz Melamine International Gmbh | Prepregs für Faserverbunde hoher Festigkeit und Elastizität |
ITMI20052035A1 (it) | 2005-10-26 | 2007-04-27 | Professional Dietetics Srl | Composizioni farmaceutiche cicatrizzanti sotto forma di crema a base di amminoacidi e sodio ialuronato |
US20080102107A1 (en) * | 2005-12-16 | 2008-05-01 | Valex Pharmaceuticals, Llc | Compositions and methods for transdermal joint pain therapy |
EP2033689A1 (en) | 2007-08-22 | 2009-03-11 | Italfarmacia S.r.l. | Injectable dermatological composition for treatment of the wrinkles |
CN102131492B (zh) * | 2008-08-27 | 2013-04-24 | 株式会社太平洋 | 含胶原肽的皮肤美容用组合物 |
FR2948286B1 (fr) * | 2009-07-27 | 2011-08-26 | Jean-Noel Thorel | Composition injectable associant un agent de comblement et un milieu de croissance des fibroblastes |
IT1396935B1 (it) | 2009-11-26 | 2012-12-20 | Solartium Entpr Ltd | Uso di una combinazione per il trattamento delle mucositi indotte da radiazioni o da chemioterapici |
EA015078B1 (ru) * | 2010-07-29 | 2011-04-29 | Елена Михайловна Хороших | Препарат и способ профилактики и коррекции патологических состояний животных |
CN104013619A (zh) * | 2014-05-27 | 2014-09-03 | 刘力 | 复方氨基酸注射液18aa-v的药物组合物和用途 |
-
2015
- 2015-12-03 SG SG11201704423SA patent/SG11201704423SA/en unknown
- 2015-12-03 ES ES15825820T patent/ES2777775T3/es active Active
- 2015-12-03 AU AU2015356587A patent/AU2015356587B2/en active Active
- 2015-12-03 CN CN201580065035.6A patent/CN106999390A/zh active Pending
- 2015-12-03 US US15/531,805 patent/US10272059B2/en active Active
- 2015-12-03 MY MYPI2017000830A patent/MY185991A/en unknown
- 2015-12-03 WO PCT/IB2015/059330 patent/WO2016088078A1/en active Application Filing
- 2015-12-03 LT LTEP15825820.2T patent/LT3226854T/lt unknown
- 2015-12-03 RU RU2017118971A patent/RU2704032C2/ru active
- 2015-12-03 EP EP15825820.2A patent/EP3226854B1/en active Active
- 2015-12-03 MX MX2017007184A patent/MX368900B/es active IP Right Grant
- 2015-12-03 PL PL15825820T patent/PL3226854T3/pl unknown
- 2015-12-03 DK DK15825820.2T patent/DK3226854T3/da active
- 2015-12-03 BR BR112017011476-3A patent/BR112017011476B1/pt active IP Right Grant
- 2015-12-03 JP JP2017529035A patent/JP6726182B2/ja active Active
- 2015-12-03 RS RS20200481A patent/RS60268B1/sr unknown
- 2015-12-03 UA UAA201705340A patent/UA120627C2/uk unknown
- 2015-12-03 CA CA2969383A patent/CA2969383C/en active Active
- 2015-12-03 KR KR1020177014925A patent/KR102429451B1/ko active IP Right Grant
-
2017
- 2017-05-31 PH PH12017501003A patent/PH12017501003B1/en unknown
- 2017-05-31 SA SA517381725A patent/SA517381725B1/ar unknown
-
2020
- 2020-04-06 CY CY20201100318T patent/CY1123040T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6726182B2 (ja) | 真皮結合組織中のフィブロエラスチンの回復用途のアミノ酸系組成物 | |
JP5642388B2 (ja) | 注射用ヒアルロン酸ゲル移植片混合物 | |
KR101779905B1 (ko) | 충전제와 섬유아세포 성장 배지를 조합한 주사용 조성물 | |
CN103415307B (zh) | 透明质酸组合物 | |
JP5539727B2 (ja) | ヒドロゲルを形成する新規な注入可能なキトサン混合物 | |
JP7481453B2 (ja) | 物理混合ha-コラーゲン皮膚充填剤 | |
TW200409653A (en) | Compositions containing peptide copper complexes and soft tissue fillers, and methods related thereto | |
Abd Samad et al. | Collagen: New dimension in cosmetic and healthcare | |
EP3416652B1 (fr) | Composition injectable; procédé de préparation de ladite composition; utilisation de ladite composition | |
EP4003288A1 (en) | Cosmetic composition with combined filler and skin regenerative effect | |
CN115670969A (zh) | 一种刺激弹性蛋白形成的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170606 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181116 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191015 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191202 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200414 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200616 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200626 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6726182 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |